Loading...
Clinical Use of DPP-4 Inhibitors
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk. Their efficacy potential to lower HbA1c is in the range between 0.5 and...
Saved in:
| Published in: | Front Endocrinol (Lausanne) |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Frontiers Media S.A.
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6593043/ https://ncbi.nlm.nih.gov/pubmed/31275246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2019.00389 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|